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Objective: To evaluate complications in pregnant women with sickle cell disease, especially
those leading to maternal death or near miss (severe obstetric complications).
Methods: A prospective cohort of 104 pregnant women registered in the Blood Center of
Belo Horizonte (Hemominas Foundation) was followed up at high-risk prenatal units. They
belonged to Group I (51 hemoglobin SS and three hemoglobin S/0-thalassemia) or Group II
(49 hemoglobin SC and one hemoglobin S/+-thalassemia). Both groups had similar median
ages. Predictive factors for ‘nearmiss’ ormaternal deathwith p-value≤0.25 in the univariate
analysis were included in a multivariate logistic model (signiﬁcance set for p-value≤0.05).
Results: Group I had more frequent episodes of vaso-occlusive crises, more transfusions in
the antepartum and postpartum, and higher percentage of preterm deliveries than Group II.
Infections and painful crises during the postpartum period were similar in both the groups.
The mortality rate was 4.8%: three deaths in Group I and two in Group II. One-third of the
women in both the groups experienced near miss. The most frequent event was pneumo-
nia/acute chest syndrome. Alpha-thalassemia co-inheritance and -gene haplotypes were
not associated with near miss or maternal death. In multivariate analysis predictors of near
miss or death were parity above one and baseline red blood cell macrocytosis. In Group I,
baseline hypoxemia (saturation<94%) was also predictive of near miss or death.
Conclusion: One-third of pregnant women had near miss and 4.8% died. Both hemoglobin SS
and SC pregnantwomen shared the same risk of death or of severe complications, especially
pulmonary events.o Bra© 2014 Associac¸ã∗ Corresponding author at: Departamento de Pediatria da Faculdade deM
Balena, 190, sala 267, 30130-100 Belo Horizonte, MG, Brazil.
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heﬁrst case description of sickle cell disease (SCD) dates back
o over a century ago. Since then, medicine and related areas
ave built a large body of knowledge on the disease. SCD prob-
bly arose on the African continent and in the Middle East
ith the slave trade being responsible for its spread to the
ew World. It has become one of the most common genetic
iseases in the world.1
Sickle cell anemia, or SS hemoglobinopathy, is the result of
ickle cell gene homozygosis. SCD also includes hemoglobin
Hb) S interactions with Hb variants other than normal Hb A.
he most common Hb variants are C (SC hemoglobinopathy),
-Punjab, and the co-inheritance of the beta thalassemia trait
Hb S/-thalassemia).1–3
Early diagnosis through newborn screening, prevention
nd treatment of complications have increased the life
xpectancyof individualswithSCD.This also accounts for SCD
omen reaching the fertile age and becoming pregnant.3,4
he extreme variability of SCD clinical phenotypes makes it
ery difﬁcult to predict the course of most pregnancies.5 The
ncidence of severe complications is high not only because
f biological aspects inherent to SCD, but also because the
isease is poorly understood by healthcare staff (‘lack of visi-
ility’), it is rarely discussed beyond the academic arena, and
here are few well-designed studies that would lead to devel-
ping appropriate protocols.
In non-pregnant women, less severe clinical forms such
s SChemoglobinopathy andS/+-thalassemia co-inheritance
ay pass unnoticed for these individuals are usually
symptomatic or oligosymptomatic and have hemoglobin
oncentrations near to or within the normal range. During
regnancy, however, these women may undergo compli-
ations as severe as those associated with the Hb SS
enotype.5,6
Several studies have reported complications in pregnant
omen with SCD, but focused only upon perinatal
utcomes.7–13 This study aims at the following: (i) gain-
ng an in-depth understanding of the proﬁle of pregnant
omen assisted by hematologists at the Blood Center of Belo
orizonte (Hemominas Foundation) and by obstetricians at
igh-risk maternities in Belo Horizonte, Minas Gerais State,
razil; (ii) describing the morbi-mortality of pregnant women
ith SCD; and (iii) investigating the causes of the most severe
omplications that led do death or near miss.
ethods
he study is built on a prospective cohort of pregnant
omen with SCD followed up at the Blood Center of Belo
orizonte (Hemominas Foundation) from December 2007 to
ovember 2011. The population comprised pregnant women
ith SCD registered in the ‘Project Aninha’, who were
reated at the Hemominas Foundation and high-risk mater-
ities in Belo Horizonte. Project Aninha was created in 2007
o provide a multidisciplinary team to support pregnant
omen with SCD at the Educational and Support Center for
emoglobinopathies (Cehmob), a center coordinated by the14;36(4):256–263 257
Unit for Newborn Screening and Genetic Diagnosis (Nupad)
of the Medicine School of the Universidade Federal de Minas
Gerais (UFMG), and the Hemominas Foundation.
The sample included a total of 104 pregnant women, 51
with the Hb SS genotype, 49 with SC hemoglobinopathy, three
with Hb S/0-thalassemia, and one with Hb S/+-thalassemia.
All cases were conﬁrmed by hemoglobin electrophoresis. The
Hb SS genotype was distinguished from Hb S/0-thalassemia
by polymerase chain reaction restriction fragment length
polymorphism (PCR-RFLP) using the Ddel restriction
enzyme.
Both hematological and obstetrical complications were
investigated, but this report focuses on hematological com-
plications. The analysis included investigating both maternal
death and the most severe complications that could lead to
maternal death (near miss). The inclusion criteria required
that the patients were pregnant at the medical appointment,
had been followed up by one of the Project Aninha partici-
pants, and had signed an informed consent to participate in
this study. The investigation was approved by Ethics Com-
mittees recognized by the Brazilian Committee for Research
Ethics (CONEP) and was carried out in accordance with the
Declaration of Helsinki (revised as of 2008).
The initial statistical analysis involved data such as age,
hemoglobinopathy type (genotype), age at menarche, number
of pregnancies, number of abortions, clinical comorbidities,
and baseline phenotypic characteristics, including hypoxemia
(baseline ﬁnger oxygen saturation<94%) identiﬁed during a
medical appointment despite a lack of symptoms, painful
crises or infections. Asymptomatic hypoxemia was conﬁrmed
by more than one evaluation at distinct clinical appointments.
Baseline hematologic values were calculated as the average of
three measurements in patients without blood transfusions
three months prior to the tests. Alloimmunization was inves-
tigated in the patients’ transfusion records before pregnancy.
The -globin gene haplotypes were determined by PCR-RFLP;
alpha-thalassemia genotypes were determined by multiple
gap PCR to detect the seven most common alpha-globin gene
deletions.
The following clinical events were recorded during preg-
nancy and during the ﬁrst 42 days postpartum: infections,
vaso-occlusive crises (exclusively those episodes which
required emergency care for intravenous hydration and the
administration of analgesia), pulmonary complications/acute
chest syndrome (pulmonary symptoms and signs associated
with new pulmonary inﬁltration as observed through chest
imaging), number of blood transfusions, and number of hospi-
talizations (days of stay). Symptomatic urinary infection was
deﬁned as urinary symptoms associated with pyuria and a
positive urine culture (>100,000 colony forming units). Posi-
tive urine culture without urinary symptoms was interpreted
as asymptomatic bacteriuria. Both symptomatic urinary infec-
tion and asymptomatic bacteriuria were grouped together for
statistical analysis.
Variables that might have contributed to maternal death
or severe clinical complications (near miss) were included
in the prognostic factors analysis. These variables were
14,15classiﬁed according to the adapted criteria for near miss.
The criteria for near miss included admission to the inten-
sive care unit, obstetric hemorrhage with hemodynamic
oter.258 rev bras hematol hem
consequences and need of transfusions, as well as clinical
criteria such as critical sickness, acute renal failure, acute
chest syndrome/pulmonary complications, sepsis, severe
hemolytic crisis, severe painful crisis, and preeclampsia.
Maternal death was that which happened during pregnancy
or within 42 days after delivery due to any direct or indirect
obstetric cause, according to the criteria established in the
10th review of the International Classiﬁcation of Diseases and
Related Health Problems (ICD-10).
Statistical methods
Univariate analysis included testing genotype associations
with total hemoglobin level, fetal hemoglobin percentage,
baseline white blood cell count, platelet count, -globin hap-
lotypes, thalassemia genotype, alloimmunization, pre- and
post-partum painful crises, pre- and post-partum blood trans-
fusions, infections, and other complications during pregnancy
and up to 42 days postpartum. The Pearson chi-squared test
or Fisher’s exact test was used to analyze qualitative variables
and Student’s t-test or the Mann–Whitney test was used for
continuous variables with or without normal distributions,
respectively.
The analysis included possible factors associated with
very severe complications (near miss) or maternal death. A
univariate analysis was carried out before proceeding to a
multivariate logistic regression analysis. Given the distinct
inherent hematological data of the two most common geno-
types, Hb SS and SC, hematological variables were analyzed
separately from other variables. A genotype-conditioned chi-
square test (Cochran statistics) was performed to check the
association of maternal death or near miss with values above
or below the medians of baseline hemoglobin, mean corpus-
cular volume (MCV), and total white blood cell, platelet, and
reticulocyte counts. The variables initially included in the
multivariate logistic regression were those which were statis-
tically signiﬁcant at p-value≤0.25 in the univariate analysis.
The ‘least signiﬁcant’ variables (with higher p-values) were
removed stepwise until only variables with p≤0.05 remained
in the model.The Statistical Package for Social Sciences (SPSS version
17.0) was used for the statistical analysis. In this study, a p-
value≤0.05 was considered statistically signiﬁcant for alpha-
type errors.
Table 1 – Characteristics of the 104 pregnant women with sickl
Characteristic Mean Standard deviation
Age at pregnancy
Hb SS/S0-thalassemia 25.4 4.8
Hb SC/S+-thalassemia 25.4 5.8
Age at menarche
Hb SS/S0-thalassemia 14.8 2.0
Hb SC/S+-thalassemia 13.1 1.4
Age at the ﬁrst hematology appointment
Hb SS/S0-thalassemia 14.6 6.5
Hb SC/S+-thalassemia 16.1 7.2
a Student’s t-test or Mann–Whitney test.2014;36(4):256–263
Results
The SS/S0-thalassemia (Group I) and SC/S+-thalassemia
(Group II) groups were similar regarding the age at the begin-
ning of pregnancy and gestational age at the ﬁrst hematology
appointment. Menarche was at a signiﬁcantly older age in
patients in Group I (Table 1). The number of pregnancies
was not signiﬁcantly different between the groups, nor were
the numbers of full-term pregnancies, stillborn babies, and
miscarriages. The prevalence of alloimmunization prior to
pregnancywas higher inGroup I, albeit not signiﬁcantly (29.6%
vs. 14.0%; p-value=0.06).
A total of 48Hb SSwomenhad BEN/CAR (45.8%) as themost
common haplotype, the homozygous CAR/CAR women repre-
sented 20.8%, and theBEN/BEN represented 18.8%.Onepatient
had the BEN/CAMhaplotype, and six others (12.5%) hadCARor
BEN heterozygous with an atypical haplotype (three CAR/Atp
and three Ben/Atp).
Out of 95 pregnant women, type 3.7 alpha-thalassemia
was found in 29 (30.5%) patients – 28 in heterozygosis and one
in homozygosis (−3.7/−3.7). Considering the Hb SS and Hb
SC genotype distribution, alpha-thalassemia was found in 20
patientswith sickle cell anemia, and in only nine patientswith
SC hemoglobinopathy (p-value=0.048).
Clinical complications
Most patients needed hospitalization (60.6%) at some time
during their pregnancy (Table 2). The between-group differ-
ence was statistically signiﬁcant: 74.1% for Group I and 46%
for Group II. Vaso-occlusive crises were the most common
cause of hospitalization in the antepartum period; they were
signiﬁcantly more frequent in Group I and occurred mostly
in the third trimester and in the puerperium. The median
hospital stay was 13 days, ranging from two to 130 days.
Most pregnant women with SCD received blood transfusions
due to symptomatic anemia (<7.0 g/dL) – increased hemol-
ysis or sudden decrease in Hb of over 2 g/dL compared to
the baseline value, or a 20% decrease in hematocrit com-
pared to the baseline level. A total of 54 (51.9%) pregnant
women received blood transfusions at some time during
their gestation period: 83.3% in Group I and 18% in Group II
(p-value=0.0001).
e cell disease.
Median Minimum Maximum p-valuea
25 16 35 0.94
26 14 37
15 9 18 <0.001
13 11 18
14 4 34 0.37
14 5 37
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Table 2 – Clinical complications of 104 pregnant women with sickle cell disease.
Complications Hb SS/S0-thalassemia Hb SC/S+-thalassemia Total p-value RR 95% CI
n % n % n %
Hospital admission
Yes 40 74.1 23 46.0 63 60.6 0.003 3.4 1.5–7.6
No 14 25.9 27 54.0 41 39.4
Transfusion during pregnancy
Yes 45 83.3 9 18.0 54 51.9 <0.0001 22.7 8.4–62.5
No 9 16.7 41 82.0 50 48.1
Painful crises during pregnancy
Yes 42 77.8 25 50.0 67 64.4 0.003 3.5 1.5–8.2
No 12 22.2 25 50.0 37 35.6
Pulmonary complications/ACS
Yes 16 29.6 16 32.0 32 30.8 0.79 1.1 0.5–2.6
No 38 70.4 34 68.0 72 69.2
Infections
Yes 38 70.4 33 66.0 71 68.3 0.63 1.3 0.5–2.5
No 16 29.6 17 34.0 33 31.7
Urinary infection
Yes 23 42.6 23 46.0 46 44.2 0.73 1.2 0.5–2.5
No 31 57.4 27 54.0 58 55.8
Sepsis
Yes 11 20.4 6 12.0 17 16.3 0.25 2.0 0.6–5.5
No 43 79.6 44 88.0 87 83.7
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The prevalence of pulmonary complications, including
cute chest syndrome, was 29.6% in Group I and 32% in
roup II (p-value=0.79). These complications occurred mainly
n the third trimester and in the puerperium (Figure 1). Sev-
ral patients experienced acute chest syndrome preceded by
ymptoms of vaso-occlusive crises (back pain, limb pain) or,
ometimes, preceded by upper airway symptoms leading to
hest pain, hypoxemia, and a new pulmonary inﬁltration,
specially of the right lung. Other clinical complications were
are but included acute renal failure, symptomatic gallstones,
nd acute splenic sequestration. Because of the small num-
ers, these complications were not statistically analyzed.
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igure 1 – Period of pulmonary complications/acute chest
yndrome.e.
Infections occurred in 68.3% of the cases. Urinary tract
infection and/or asymptomatic bacteriuria accounted for
44.2% of the cases. No statistically signiﬁcant difference
was found between Groups I and II. One patient with SC
hemoglobinopathy developed pyelonephritis that progressed
to severe sepsis, multiple organ failure, and death in the 32nd
week of pregnancy, notwithstanding the treatment provided.
Infections in other organs or systems occurred less often; they
were more common, albeit with no statistically signiﬁcant
difference, in Group I. These infections included endometri-
tis, tonsillitis, septic arthritis, cholecystitis, skin infections, leg
ulcers, and mastitis. One patient with sickle cell anemia had
acute aplastic crises due to parvovirus infection. Thediagnosis
was conﬁrmed through the detection of viral genome during
the acute viral infection period.
Five deaths were registered out of 104 pregnancies (4.8%).
Four were due to acute chest syndrome (two in Hb SS, one
in Hb S/0-thalassemia and one in Hb SC patients); the ﬁfth
death was of a pregnant woman with Hb SC and sepsis origi-
nating from the urinary tract. One patient died in the second
trimester, and the remaining four in the puerperium, three of
them after severe symptoms of pulmonary complications that
started in the third trimester and forced delivery.
Near miss were registered in 16 pregnant women in Group I
and 18 in Group II. Summing up death and near miss (the out-
come of ‘near/death’), a total of 39 pregnant women (37.5%)
died or had near miss, while the remaining had either non-
speciﬁc or mild to moderate complications. No statistically
signiﬁcant difference was found between Groups I and II (p-
value=0.69).
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Figure 2 – Near-miss and maternal death causes according
themedianat the start of pregnancy (p-value=0.22),menarcheto genotype.
Pulmonary complications were the main cause for
‘near/death’ in 26 of 39 pregnant women (66.7%; Figure 2).
Severe acute chest syndrome leading to adult respiratory dis-
tress syndrome (ARDS), acute respiratory failure and the need
formechanical ventilation occurred in six patients – four cases
in Group I and two in Group II.
Sepsis occurred in 17 cases, including those that suffered
septic shock due to pulmonary complications. Two cases
evolved to death: one in Group I (septic shock due to pul-
monary complications on the 42nd day of puerperium) and
one in Group II, secondary to pyelonephritis.
Table 3 – Univariate analysis of hematological variables predict
Variable Below median Above median
n % n %
Fetal hemoglobin
Near-miss 20 32.8 19 44.2
No near-miss 41 67.2 24 55.8
Baseline hemoglobin
Near-miss 24 46.2 15 28.8
No near-miss 28 53.8 37 71.2
Baseline MCV
Near-miss 14 28.0 25 47.2
No near-miss 36 72.0 28 52.8
Baseline WBC count
Near-miss 16 30.2 23 45.1
No near-miss 37 69.8 28 54.9
Baseline platelet count
Near-miss 19 36.5 20 38.5
No near-miss 33 63.5 32 61.5
Baseline reticulocyte count
Near-miss 20 38.5 19 36.5
No near-miss 32 61.5 33 63.5
RR: Relative risk; 95% CI: 95% conﬁdence interval: MCV: mean corpuscular
a Medians of each hematologic variable were calculated for Group I (SS an
two groups were aggregated and the chi square test was applied to ident
of hematologic variables.2014;36(4):256–263
Multiple organ failure including liver impairment, dissem-
inated intravascular coagulation, renal failure and pulmonary
failure occurred in six cases – three in Group II (one end-
ing up in death) and three in Group I (also leading to death
in one case). The latter occurred in a patient with Hb S/0-
thalassemia on the 10th day of puerperium.
In general, patients experienced more than one severe
complication, for instance, an association of acute chest syn-
drome with sepsis or multiple organ failure. Other causes of
near miss were severe preeclampsia in four cases (two in each
group) andhemorrhageafter birth in four cases (three inGroup
I and one in Group II). Severe hemolytic crises occurred in two
cases in Group II, an acute splenic sequestration in Group II,
and a severe painful crisis, also in Group II. Stroke occurred
in a patient with Hb SS after fetal death in the 27th week of
gestation. An acute aplastic crisis due to parvovirus occurred
in one Hb SS patient as mentioned previously.
Table 3 shows the univariate analysis for hematologic
variables predictive of “near/death”. Following the statistical
methodology adopted in this study, only the mean baseline
Hb (p-value=0.07), the mean baseline MCV (p-value=0.05) and
the mean baseline white blood cell count (p-value=0.12) were
included in the multivariate logistic model. No statistically
signiﬁcant association was found between “near/death” and
S haplotypes or co-inheritance of alpha-thalassemia. Table 4
shows the results of other factors predicting “near/death”. Fol-
lowing the same statistical criterion, patient’s age greater thanat age ≥14 years (p-value=0.03), parity > 1 (p-value=0.17) and
baseline hypoxemia (p-value=0.05) were initially included in
the multivariate logistic model.
ive of maternal death or near miss (near-death).a
Total p-value RR 95% CI
n %
39 37.5 0.24 1.6 (0.7–3.6)
65 62.5
39 37.5 0.07 2.1 (0.9–4.8)
65 62.5
39 37.9 0.05 2.3 (1.0–5.2)
64 62.1
39 37.5 0.12 1.9 (0.8–4.2)
65 62.5
39 37.5 0.84 1.1 (0.5–2.4)
65 62.5
39 37.5 0.84 0.9 (0.4–2.0)
65 62.5
volume; WBC: white blood count.
d S0-thalassemia) and Group II (SC and S+-thalassemia). Then, the
ify any association of near miss/death with high/low median values
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Table 4 – Univariate analysis of clinical variables predictive of maternal death or near miss.
Occurrence of near miss or death (‘near/death’) Group I Group II p-valuea
n % n %
Median age (>25 years of age) 10 38.5 13 48.1 0.22
Adolescent 2 40.0 1 16.7 0.45
Pre-‘near/death’ alloimmunization 7 43.8 2 28.6 0.78
Menarche at age>14 15 46.9 3 42.9 0.03
Parity > 1 10 40.0 11 50.0 0.17
>2 transfusions pre-‘near/death’ 6 27.3 - - 0.31
Painful crises pre-‘near/death’ 16 38.1 9 45.0 0.32
Urinary infection 9 39.1 10 43.5 0.49
Baseline oxygen saturation<94% 9 56.3 - - 0.05
Pre-‘near/death’ preeclampsia - - 1 5.0 0.39
Co-inheritance of alpha-thalassemia 7 35.0 1 11.1 0.40
a Cochran test (chi-square of conditional independence).
Table 5 – Multivariate analysis of prognostic factors for maternal death or near miss in 94 pregnant women with SCD.
Factors Relative risk 95% conﬁdence interval p-value
Genotype 1.8 0.64–5.13 0.26
Baseline mean corpuscular volume 3.1 1.21–7.73 0.02
Parity > 1 2.6 1.03–6.52 0.04
Baseline oxygen saturation<94% 4.3 1.09–16.97 0.04
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Table 5 shows the ﬁnal multivariate logistic model of the
ssociation between “near/death” and the predictors selected
hrough the univariate model. Upon adjusting for genotype,
nly parity > 1, baseline hypoxemia, and baseline MCV higher
han the median remained statistically signiﬁcant in the
odel.
iscussion
he high rate of complications in pregnant patients with SCD
as already been reported in previous studies. Complications
nclude an increased number of cesarean deliveries, preterm
irths, restricted intrauterine growth, and low weight babies,
specially in pregnant women with the homozygous form
f the disease (Hb SS). Increased numbers of vaso-occlusive
rises, more frequently in the third trimester and in the puer-
erium, aswell as increasednumbers of caseswith acute chest
yndrome have also been associated with substantial mater-
al morbidity and mortality.7–13 In this study, the number of
omplications was high among pregnant women with SCD:
0.6%were admitted to hospital at least once for reasons other
hanassisting the birth,miscarriages or puerperium,more fre-
uently in Group I. A higher rate of painful crises was found in
his study when compared to others in the literature.7–13 One
ain reason for this might be the concept of painful crises
dopted in the present study, which set as criteria the need
f administering venous analgesia and hydration and is thus
ot limited to episodes of drug administration. The prevalence
f infections was similar to those reported in previous stud-
es, with no signiﬁcant differences between the Hb SS and Hb
C genotypes. Urinary tract infections were also more preva-
ent in this study as it included patients with asymptomatic
acteriuria.t completely available for ten participants.
Blood transfusions during pregnancy were more common
in Group I. Symptomatic anemia secondary to various compli-
cations was the main reason for blood transfusions. Based on
a prospective and randomized study, Koshy et al.16 suggested
that resorting to prophylactic transfusion does not signiﬁ-
cantly decrease the rate of maternal and fetal mortality, but
increases the risk of transfusion reactions and alloimmuniza-
tion, and leads to hemosiderosis. Even with more stringent
indications for blood transfusions, over half of the pregnant
women in this study needed at least one transfusion. Among
Hb SS patients, the frequency of transfusions (83.3%) was
similar to that in other studies.17 Exchange transfusion was
needed in 20% of the pregnant women, mainly for acute chest
syndrome and stroke.
Pulmonary complications included acute chest syndrome
and classic pneumonia. The main cause of maternal death or
nearmiss in this studywas acute chest syndrome,with similar
risks for pregnant women with the Hb SC and Hb SS sub-
types. Previous studies have already identiﬁed an increased
mortality rate in pregnant women with SC hemoglobinopa-
thy, especially in the third trimester and in the puerperium.6,18
The literature shows conﬂicting results regarding the relative
severity of complications in pregnant women with Hb SS and
SC hemoglobinopathy.7–10
Moreover, previous studies have reported increased inci-
dences of thromboembolism and pulmonary infarct, which
are usually fatal, in pregnant women with Hb SS and SC
hemoglobinopathies.5,18–21 These complications might occur
anytime during pregnancy, childbirth, or puerperium, but they
are more common in the third trimester and in the puer-
perium. They even can be the ﬁrstmanifestation of the disease
in previously oligosymptomatic patients, such as in pregnant
women with Hb SC or Hb S/+-thalassemia.20,21 The risk of
oter.
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maternal death is higher during the third trimester and the
puerperium,22 probably due to variations in hormones, hyper-
coagulability and increased susceptibility to infections during
these periods.4 In the current study, one third of the pregnant
women had pulmonary complications, which was the reason
for four deaths due to acute respiratory failure, regardless of
the treatment provided.
The haplotypes of the S gene [Benin and Bantu (CAR)]
were not signiﬁcantly associated with near miss death in this
study. Similar to the study by Belisário et al.,23 this study
did not ﬁnd statistically signiﬁcant differences between hap-
lotypes regarding the clinical manifestations in sickle cell
anemia. Furthermore, co-inheritance of alpha-thalassemia
was not associated with near miss/death. Similarly, other
studies24,25 did not ﬁnd any signiﬁcant association between
co-inheritance of alpha-thalassemia and protection against
acute chest syndrome.
Themortality ratewas 4.8%,which ismuchhigher than the
ﬁgures reported in recent studies, but it should be stressed that
the pregnant women in the present study were all followed up
at high-risk prenatal units. In addition, three of the deceased
womenalreadyhad severemedical conditionswhen theywere
admitted to hospital.
In the univariate analysis, late menarche was associated
with near miss/death, probably meaning major organ injury,
that is, a delayed sexual maturation could be indicative of the
clinical severity of the underlying disease and, therefore, may
suggest a higher susceptibility to complications and a higher
risk of near miss and maternal death.
Several hematologic variables were associated with near
miss/death in the univariate analysis. However, only macro-
cytosis (increased MCV) remained as a signiﬁcant variable in
the multivariate analysis. Pregnant women with MCV higher
than the median had a three times higher risk of develop-
ing near miss or maternal death than those with lower MCV.
Macrocytosis may be a surrogate for increased hemolysis, and
thus a more severe underlying disease.
HbSSpatientswithbaselinehypoxemiawere found tohave
a four-time higher risk of facing near miss or maternal death.
Patients who have baseline hypoxemia are usually those with
a more severe form of the disease.26 It is, therefore, important
to determine the baseline oxygen saturation in these women
at the beginning of the prenatal period, as it could be a marker
of disease severity and complications during pregnancy.
Parity > 1 was also identiﬁed as a higher risk (two times)
for near miss/death in this study. The reason for this remains
unclear. A hypothesis is that pregnancy-driven physiologic
changes could pose more risk to the pregnant women with
SCD, a risk that is proportionally higher as the number of
gestations and accumulated complications deriving from the
disease increases.
The major follow-up recommendations for SCD pregnant
women consist of carefully monitoring hematologic,
obstetrical and fetal complications, and recognizing SCD
complications as early as possible.27 The type of delivery
should be indicated by obstetric considerations, but it is crit-
ical to take precautions during labor and childbirth in order
to prevent vaso-occlusion and pain, such as maintaining the
temperature to avoid hypothermia, acidosis and hypoxemia.
Blood transfusions are indicated for acute and severe episodes2014;36(4):256–263
during pregnancy complications that may be enhanced by
SCD.27,28 Partial exchange transfusions should be indicated
as early as possible after the beginning of symptoms of acute
chest syndrome, especially when the hematocrit is equal to
or higher than 25%.29 Critical care should be delivered by a
concerted team composed by hematologists, obstetricians,
general practitioners and intensivists.30
Providing genetic counseling and educating SCD women
about their disease and complications some time before
a potential pregnancy are crucial items of care for these
patients. They should be warned about the need of spe-
cialized gynecologic control and follow up with adequate
contraception techniques, if they wish. It is critical to provide
educational training at government health clinics so that the
care staff can follow up patients as early as adolescence and
help them plan their pregnancy when they are ready. Decid-
ingwhich contraceptivemethod is themost adequate is a joint
decision between the doctor and the patient.31
Once pregnant, women with SCD should be followed up by
a multidisciplinary team at a specialized center for prenatal
care. This team should include a hematologist, who will be
responsible for detecting signs and symptoms that might ﬂag
potentially severe complications that require the patient to be
immediately referred to a hospital specialized in emergency
care for pregnant women with SCD.
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